Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 28%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is well-positioned to capitalize on the growing demand for insulin pumps, particularly in the underserved Type 1 diabetes market. The company has a diversified portfolio of technologies, with its newest insulin pump Mobi entering the market soon and its innovative tubeless patch pump Sigi in development. These developments, coupled with Tandem Diabetes Care's strong customer retention, give us confidence in the company's growth potential. Additionally, the shift towards pharmacy channel sales could lead to higher revenue and margins in the long term. Although there are some risks, such as supply chain disruptions and potential competition from GLP-1s, we believe the company's efforts to expand its market reach and focus on sustainability make it a strong investment opportunity.

Bears say

Tandem Diabetes Care is expected to face challenges in expanding its market share, as it operates in a highly competitive environment and faces potential threats from new entrants. The company's heavy reliance on insulin pumps for the majority of its revenue also poses concerns, particularly as GLP-1s, a potential competitor, could pose a significant threat. Additionally, Tandem's transition to a Pay/Go model may negatively impact its near-term revenues, but the long-term benefits of this model should drive growth and profitability. With a lower profit margin than its peers and potential execution risks, we believe a discounted valuation is warranted, and have a $31 price target for the stock.

TNDM has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 28% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 18 analysts, TNDM has a Buy consensus rating as of Sep 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.